122 related articles for article (PubMed ID: 35724381)
1. Potential Medicare Part D Savings on Generic Drugs From the Mark Cuban Cost Plus Drug Company.
Lalani HS; Kesselheim AS; Rome BN
Ann Intern Med; 2022 Jul; 175(7):1053-1055. PubMed ID: 35724381
[No Abstract] [Full Text] [Related]
2. Projected Savings for Generic Oncology Drugs Purchased via Mark Cuban Cost Plus Drug Company Versus in Medicare.
Cortese BD; Dusetzina SB; Luckenbaugh AN; Al Hussein Al Awamlh B; Stimson CJ; Barocas DA; Penson DF; Chang SS; Talwar R
J Clin Oncol; 2023 Oct; 41(29):4664-4668. PubMed ID: 37290029
[TBL] [Abstract][Full Text] [Related]
3. Potential Cost Savings in Medicare Part D Across Gastroenterology: An Assessment of Alternative Drug Sourcing.
Bouvette CA; Bouvette M; Yohannan B; Rumman A; Ali I
Am J Gastroenterol; 2024 Apr; 119(4):764-767. PubMed ID: 38084855
[TBL] [Abstract][Full Text] [Related]
4. Brand Medications and Medicare Part D: How Eye Care Providers' Prescribing Patterns Influence Costs.
Newman-Casey PA; Woodward MA; Niziol LM; Lee PP; De Lott LB
Ophthalmology; 2018 Mar; 125(3):332-339. PubMed ID: 28625684
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of Potential Urologic Prescription Drug Savings With Mark Cuban Cost Plus Drug Company.
Schloegel V; Harris L; Harris A; Dropkin B
Urol Pract; 2024 Mar; 11(2):276-282. PubMed ID: 38377158
[TBL] [Abstract][Full Text] [Related]
6. Encouraging generic use can yield significant savings.
Zimmerman C
Find Brief; 2012 Nov; 15(8):1-3. PubMed ID: 23213854
[TBL] [Abstract][Full Text] [Related]
7. Variation in generic dispensing rates in Medicare Part D.
Buttorff C; Xu Y; Joyce G
Am J Manag Care; 2020 Nov; 26(11):e355-e361. PubMed ID: 33196286
[TBL] [Abstract][Full Text] [Related]
8. Urological Drug Price Stewardship: Potential Cost Savings Based on the Mark Cuban Cost Plus Drug Company Model.
Cortese BD; Chang SS; Talwar R
J Urol; 2023 Feb; 209(2):309-311. PubMed ID: 36413174
[No Abstract] [Full Text] [Related]
9. Impact of cost sharing on prescription drugs used by Medicare beneficiaries.
Goedken AM; Urmie JM; Farris KB; Doucette WR
Res Social Adm Pharm; 2010 Jun; 6(2):100-9. PubMed ID: 20511109
[TBL] [Abstract][Full Text] [Related]
10. Patient-Level Savings on Generic Drugs Through the Mark Cuban Cost Plus Drug Company.
Kouzy R; El Alam MB; Corrigan KL; Lalani HS; Ludmir EB
JAMA Health Forum; 2024 Jun; 5(6):e241468. PubMed ID: 38874962
[TBL] [Abstract][Full Text] [Related]
11. Impact of final short-fill rule on Medicare Part D costs and long-term care pharmacy dispensing.
Bazalo G; Weiss RC
Consult Pharm; 2012 Apr; 27(4):269-73. PubMed ID: 22498986
[TBL] [Abstract][Full Text] [Related]
12. Cost savings from Medicare Part D plan comparisons.
O'Connell MB; Pelaccio K; Tabon PK; Rashid Z; Na SY; Thomas H
J Am Geriatr Soc; 2024 Apr; 72(4):1275-1279. PubMed ID: 38241188
[No Abstract] [Full Text] [Related]
13. In Medicare Part D plans, low or zero copays and other features to encourage the use of generic statins work, could save billions.
Hoadley JF; Merrell K; Hargrave E; Summer L
Health Aff (Millwood); 2012 Oct; 31(10):2266-75. PubMed ID: 23048108
[TBL] [Abstract][Full Text] [Related]
14. Estimated Medicare Part D Savings From Generic Drugs With a Skinny Label.
Egilman AC; Kesselheim AS; Sarpatwari A; Rome BN
Ann Intern Med; 2024 Jun; 177(6):833-835. PubMed ID: 38684101
[No Abstract] [Full Text] [Related]
15. Potential savings associated with drug substitution in Medicare Part D: the Translating Research into Action for Diabetes (TRIAD) study.
Duru OK; Ettner SL; Turk N; Mangione CM; Brown AF; Fu J; Simien L; Tseng CW
J Gen Intern Med; 2014 Jan; 29(1):230-6. PubMed ID: 23975059
[TBL] [Abstract][Full Text] [Related]
16. Impact of U.S. federal and state generic drug policies on drug use, spending, and patient outcomes: A systematic review.
Mishuk AU; Fasina I; Qian J
Res Social Adm Pharm; 2020 Jun; 16(6):736-745. PubMed ID: 31445986
[TBL] [Abstract][Full Text] [Related]
17. Medicare Part D Plans Rarely Cover Brand-Name Drugs When Generics Are Available.
Dusetzina SB; Cubanski J; Nshuti L; True S; Hoadley J; Roberts D; Neuman T
Health Aff (Millwood); 2020 Aug; 39(8):1326-1333. PubMed ID: 32744944
[TBL] [Abstract][Full Text] [Related]
18. Medicare Part D Payments for Generic Imatinib From 2017 to 2023.
Dusetzina SB
JAMA Intern Med; 2024 Jan; 184(1):104-105. PubMed ID: 37983024
[TBL] [Abstract][Full Text] [Related]
19. Relief in Sight - Estimated Savings under Medicare Part D Redesign.
Dusetzina SB
N Engl J Med; 2021 Dec; 385(26):e93. PubMed ID: 34758246
[No Abstract] [Full Text] [Related]
20. Association of Rising Cost and Use of Oral Anticancer Drugs With Medicare Part D Spending From 2013 Through 2017.
Seiger K; Mostaghimi A; Silk AW; Schmults CD; Ruiz ES
JAMA Oncol; 2020 Jan; 6(1):154-156. PubMed ID: 31697307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
